Abstract: DWP-450, Purified Botulinum Toxin Type A, for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Subjects: Results from Two Randomized, Double-Blind, Placebo-Controlled, Single Dose Phase III Safety and Efficacy Studies
نویسنده
چکیده
M oday, O cber 9, 2017 1.65cc of Volbella. All patients had uneventful procedural courses. Post-procedure, 7 patients (8.6%) reported swelling, and 5 (6.1%) required an oral course of methylprednisolone to reduce inflammation. No patients experienced the Tindell effect or contour abnormalities, and no patients required dissolution of filler. There were no instances of skin necrosis, tissue injury, or intravascular injection. All 81 patients were satisfied with their aesthetic results, and no patients requested or were advised to have filler dissolution.
منابع مشابه
Abstract: DWP-450, Purified Botulinum Toxin Type A, for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Subjects: Results from a Multi-Center, Open Label, Repeat Dose, Long Term Exposure, Year Long Phase II Safety Study
M oday, O cber 9, 2017 1.65cc of Volbella. All patients had uneventful procedural courses. Post-procedure, 7 patients (8.6%) reported swelling, and 5 (6.1%) required an oral course of methylprednisolone to reduce inflammation. No patients experienced the Tindell effect or contour abnormalities, and no patients required dissolution of filler. There were no instances of skin necrosis, tissue inju...
متن کاملA double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
BACKGROUND Several randomized, controlled studies have reported benefits of botulinum toxin type A (BoNTA; Allergan Inc., Irvine, CA, USA) over placebo in the treatment of migraine. Some studies reported significant benefits at dosages as low as 16 U, while other studies reported safety, tolerability, and efficacy at dosages up to 260 U. However, the optimal treatment paradigm and patient popul...
متن کاملAn analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
BACKGROUND A new formulation of a botulinum neurotoxin type A (BoNTA-ABO; Dysport [abobotulinumtoxinA]; Medicis Aesthetics, Scottsdale, AZ) was recently approved by the US Food and Drug Administration for the treatment of moderate to severe glabellar lines. OBJECTIVE This article summarizes the safety data from five phase III clinical trials investigating the use of BoNTA-ABO in the treatment...
متن کاملMove Over Botox -- There’s a New Kid in Town Evaluation of Variable-Dose Treatment With a New U.S. Botulinum Toxin Type A (Dysport) for Correction of Moderate to Severe Glabellar Lines: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Background: Botulinum toxin type A has been shown to reduce the activity of glabellar muscles, decreasing the occurrence of expression-related facial lines. In April 2009, the U.S. Food and Drug Administration (FDA) approved a new formulation called Dysport. Objective: To evaluate the safety, efficacy, and duration of response of variable-dosed Dysport in the treatment of moderate to severe gla...
متن کاملAn analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
BACKGROUND A new formulation of a botulinum neurotoxin type A (BoNTA-ABO; Dysport [abobotulinumtoxinA], Medicis Aesthetics, Scottsdale, AZ) has recently been approved in the United States for the treatment of moderate to severe glabellar lines. OBJECTIVE We describe the results of four phase III studies of BoNTA-ABO for the treatment of glabellar lines. METHODS Of the four studies reported ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 5 شماره
صفحات -
تاریخ انتشار 2017